Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

J&J inks $6.5bn all-cash deal to acquire Momenta

J&J inks $6.5bn all-cash deal to acquire Momenta

J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.

Latest news

More from news
Approximately 15 fully matching, plus 73 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

  • Taking a strategic approach Taking a strategic approach

    Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for

  • Back to the future Back to the future

    Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.